These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 23346997)

  • 1. Two-step evolution of the hepatitis B drug-resistant mutations in a patient who developed primary entecavir resistance.
    Lee GH; Inoue M; Toh JK; Chong RH; Aung MO; Koay ES; Lim SG
    Liver Int; 2013 Apr; 33(4):642-6. PubMed ID: 23346997
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatitis B virus quasispecies susceptibility to entecavir confirms the relationship between genotypic resistance and patient virologic response.
    Baldick CJ; Eggers BJ; Fang J; Levine SM; Pokornowski KA; Rose RE; Yu CF; Tenney DJ; Colonno RJ
    J Hepatol; 2008 Jun; 48(6):895-902. PubMed ID: 18362040
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Three years of continuous entecavir therapy in treatment-naïve chronic hepatitis B patients: VIRAL suppression, viral resistance, and clinical safety.
    Yuen MF; Seto WK; Fung J; Wong DK; Yuen JC; Lai CL
    Am J Gastroenterol; 2011 Jul; 106(7):1264-71. PubMed ID: 21364549
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term continuous entecavir therapy in nucleos(t)ide-naïve chronic hepatitis B patients.
    Ono A; Suzuki F; Kawamura Y; Sezaki H; Hosaka T; Akuta N; Kobayashi M; Suzuki Y; Saitou S; Arase Y; Ikeda K; Kobayashi M; Watahiki S; Mineta R; Kumada H
    J Hepatol; 2012 Sep; 57(3):508-14. PubMed ID: 22659518
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Virological response and antiviral resistance mutations in chronic hepatitis B subjects experiencing entecavir therapy: an Indian subcontinent perspective.
    Ismail AM; Sharma OP; Kumar MS; Eapen CE; Kannangai R; Abraham P
    Antiviral Res; 2013 May; 98(2):209-16. PubMed ID: 23485939
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment response and evolution of HBV resistance during lamivudine plus adefovir or entecavir therapy in patients with adefovir-resistant mutants.
    Chen CH; Wang JH; Lu SN; Hu TH; Hung CH; Chang MH; Changchien CS; Lee CM
    Antivir Ther; 2012; 17(4):701-9. PubMed ID: 22358132
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emergence of entecavir-resistant mutations in nucleos(t)ide-naive Japanese patients infected with hepatitis B virus: virological breakthrough is also dependent on adherence to medication.
    Kamezaki H; Kanda T; Wu S; Nakamoto S; Arai M; Maruyama H; Fujiwara K; Imazeki F; Yokosuka O
    Scand J Gastroenterol; 2011 Sep; 46(9):1111-7. PubMed ID: 21623676
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selection of an entecavir-resistant mutant despite prolonged hepatitis B virus DNA suppression, in a chronic hepatitis B patient with preexistent lamivudine resistance: successful rescue therapy with tenofovir.
    Leemans WF; Niesters HG; van der Eijk AA; Janssen HL; Schalm SW; de Man RA
    Eur J Gastroenterol Hepatol; 2008 Aug; 20(8):773-7. PubMed ID: 18617782
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of entecavir in lamivudine-refractory patients with chronic hepatitis B: randomized controlled trial in Japanese patients.
    Suzuki F; Toyoda J; Katano Y; Sata M; Moriyama M; Imazeki F; Kage M; Seriu T; Omata M; Kumada H
    J Gastroenterol Hepatol; 2008 Sep; 23(9):1320-6. PubMed ID: 18554238
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular characterization of a novel entecavir mutation pattern isolated from a multi-drug refractory patient with chronic hepatitis B infection.
    Karatayli E; Karatayli SC; Cinar K; Gokahmetoglu S; Güven K; Idilman R; Yurdaydin C; Bozdayi AM
    J Clin Virol; 2012 Feb; 53(2):130-4. PubMed ID: 22078148
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of hepatitis B virus drug-resistant mutant haplotypes by ultra-deep pyrosequencing.
    Ko SY; Oh HB; Park CW; Lee HC; Lee JE
    Clin Microbiol Infect; 2012 Oct; 18(10):E404-11. PubMed ID: 22757653
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of entecavir treatment for lamivudine-resistant hepatitis B over 3 years: histological improvement or entecavir resistance?
    Suzuki Y; Suzuki F; Kawamura Y; Yatsuji H; Sezaki H; Hosaka T; Akuta N; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kobayashi M; Miyakawa Y; Kumada H
    J Gastroenterol Hepatol; 2009 Mar; 24(3):429-35. PubMed ID: 19226381
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk factors of gene-resistant mutations in different nucleosides.
    An P; Bian L; Yin B; Lv D; Cao YX; Wu X
    Hepatogastroenterology; 2012; 59(113):228-30. PubMed ID: 22260834
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Entecavir resistance in entecavir naive lamivudine treated chronic hepatitis B patients].
    Sayan M; Hülagü S; Akhan SC; Sentürk O; Meriç M; Cekmen M
    Mikrobiyol Bul; 2009 Jul; 43(3):425-32. PubMed ID: 19795617
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Drug-resistant genes at hepatitis B virus polymerase region during entecavir treatment].
    Guo XF; Zhang CX; Liu Y; Wu F; Luo X
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2013 Aug; 35(4):444-6. PubMed ID: 23987494
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Do different lamivudine-resistant hepatitis B genotypes carry the same risk of entecavir resistance?
    Lee GH; Aung MO; Dan YY; Lee YM; Mak B; Low HC; Lim K; Thwin MA; Tan PS; Lim SG
    J Med Virol; 2013 Jan; 85(1):26-33. PubMed ID: 23023992
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical characteristics and effect of secondary individualized therapy in chronic hepatitis B patients infected with the rtA181 mutation hepatitis B virus].
    Ji FZ; Wang L; Yang BH; Zhao JJ; Liu F; Xue Y; Li T
    Zhonghua Gan Zang Bing Za Zhi; 2012 Apr; 20(4):280-4. PubMed ID: 22964149
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Undetectable HBV DNA at month 12 of entecavir treatment predicts maintained viral suppression and HBeAg-seroconversion in chronic hepatitis B patients at 3 years.
    Wong GL; Wong VW; Chan HY; Tse PC; Wong J; Chim AM; Yiu KK; Chu SH; Chan HL
    Aliment Pharmacol Ther; 2012 Jun; 35(11):1326-35. PubMed ID: 22506552
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dynamics of hepatitis B virus resistance to entecavir in a nucleoside/nucleotide-naïve patient.
    Guo JJ; Li QL; Shi XF; Zhang DZ; Zeng AZ; Feng T; Huang AL
    Antiviral Res; 2009 Feb; 81(2):180-3. PubMed ID: 18948142
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stepwise process for the development of entecavir resistance in a chronic hepatitis B virus infected patient.
    Villet S; Ollivet A; Pichoud C; Barraud L; Villeneuve JP; Trépo C; Zoulim F
    J Hepatol; 2007 Mar; 46(3):531-8. PubMed ID: 17239478
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.